Castrate Resistant Prostate Cancer Enhertu Therapy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18+
SponsorWashington D.C. Veterans Affairs Medical Center
About this trial
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Eligibility criteria
Qualifiers
Pathologically confirmed adenocarcinoma of the prostate
Diagnosis of mCRPC
Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen
Ongoing ADT to maintain serum testosterone levels below 50 ng/dL
Disqualifiers
History of interstitial lung disease or pneumonitis requiring steroids
Significant coronary vascular disease
Previous exposure to HER2 targeted therapy
Trial design
Treatments tested in this trial
- Enhertu
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Washington D.C. Veterans Affairs Medical Center
Lead sponsor
Daiichi Sankyo
Collaborator
Cancer Research And Biostatistics
Collaborator
Institute for Clinical Research
Collaborator
Source ClinicalTrials.gov